Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease（NAFLD）
Status:
Not yet recruiting
Trial end date:
2024-02-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of HSK31679 tablets compared
with placebo in reducing low-density lipoprotein cholesterol (LDL-C) and MRI-PDFF after 12
weeks of treatment in patients with hypercholesterolemia and non-alcoholic fatty liver
disease (NAFLD).